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Abstract Recently we have shown that PKC pi and P2 are able 
to inhibit the tyrosine kinase activity of the human insulin 
receptor (HIR). Now we have investigated whether a distinct 
PKC isoform might be involved in the inhibitory effect of T N F a 
on insulin signaling in HEK293 cells. T N F a induces a rapid 
translocation of the PKC isoform e (TNFa 10 9 M, maximal 
effect within 5-10 min) in rat-1 fibroblasts, while no effect 
occurred on other isoforms. Cotransfection of HIR with PKC e 
did not significantly reduce the insulin stimulated receptor kinase 
activity; however, when cells were incubated with T N F a for 10 
min (10 9 M) a 62 ± 17% (n = 5) inhibition of the insulin receptor 
kinase activity was observed which was significantly ( P < 0 . 0 1 ) 
higher than that observed in cells which were not transfected with 
PKC (32 ± 11.5%, n - 5). The data suggest that translocation of 
PKC e induced by TNFa enables this PKC isoform to interact 
with insulin signaling and to inhibit the insulin receptor kinase 
activity. 
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1. Introduction 
Protein kinase C (PKC) plays a key role in t ransmembrane 
signal transduction of several hormones, growth factors, and 
neurotransmitters. In recent years different isoenzymes have 
been identified and characterized according to their molecular 
and biochemical properties [1,2]. They represent a family of 
structurally and functionally related serine/threonine kinases 
which are derived from multiple genes as well as from alter-
native splicing of single m R N A transcripts [1,2]. The isoforms 
differ in their regulatory domains and dependence on Ca 2 + , as 
well as in their tissue distribution. Due to those character-
istics, P K C isoforms can be subdivided into three major 
groups: classical, Ca 2 + -dependent cPKC isoforms (a, p i , 
P2, y), new, Ca 2 +- independent n P K C isoforms (8, e, r\, 9), 
and atypical a P K C isoforms (£, A.). Activation of P K C seems 
to be associated with intracellular redistribution of the enzyme 
to the plasma membrane [1,2]. There is multiple evidence that 
PKC might be important as a modula tor of insulin receptor 
function [3-5]. In addition we have shown that hyperglycemia 
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induced insulin receptor inhibition seems to be mediated by 
P K C as well [6]. To investigate which P K C isoforms are in-
hibitory for the insulin receptor kinase activity we have re-
cently studied the interaction of the insulin receptor with dif-
ferent P K C isoforms. HEK293 cells were transiently 
cotransfected with insulin receptor and the P K C isoforms a, 
p i , P2, y, 5, e, £ and 6. After a prestimulation of the cells with 
phorbol esters we found that the P K C isoforms p i and P2 
were able to inhibit the insulin receptor kinase activity while 
other isoforms had no effect [7]. In another study in C H O 
cells an inhibitory effect on the insulin receptor activity could 
only be observed with P K C a [8]. Different mediators of in-
sulin resistance have been discussed. Spiegelman et al. pro-
posed a predominant role for T N F a in obesity induced insu-
lin resistance based on studies in animal models, cell models 
as well as studies from human tissues [9-12]. In the present 
paper we have studied the impact of P K C on the T N F a 
induced insulin receptor kinase inhibition. Available data sug-
gest that T N F a can activate PKC in certain cell lines [13-15]; 
however, there are at present no data concerning the question 
whether this activation of P K C is involved in the inhibition of 
insulin signaling. We have studied whether a specific isoform 
of P K C can be activated by T N F a and might be involved in 
the inhibition of insulin receptor kinase activity. 
2. Material and methods 
Cell culture reagents and fetal calf serum (FCS) were purchased 
from Gibco (Eggenstein, Germany); culture dishes were from Greiner 
(Frickenhausen, Germany). Human recombinant insulin was from 
Hoechst (Frankfurt, Germany). Aprotinin, phenylmethylsulfonyl flu-
oride (PMSF), Na3V04 , Triton X-100, and dithiothreitol (DTT) were 
from Sigma (Munich, Germany). Reagents for SDS-PAGE and West-
ern blotting were obtained from Roth (Karlsruhe, Germany) and Bio-
Rad (Munich, Germany). Nitrocellulose was from Schleicher&Schuell 
(Dassel, Germany). Enhanced chemiluminescence reagents (ECL) 
were from Amersham (Braunschweig, Germany). Anti-pTyr antibody 
(PY20) was from Leinco (Baldwin, PA, USA). The insulin receptor 
antibody against the C-terminal domain of the (3-subunit (aCT104) 
was described earlier [6]. Polyclonal PKC isoform e antibody was 
purchased from Gibco (Eggenstein, Germany), and pan-PKC anti-
body was from UBI (Lake Placid, NY, USA), Qiagen Plasmid Kit 
was from Diagen (Hilden, Germany). 
2.1. Transient expression of HIR and PKC isoforms in HEK 293 cells 
The cDNA for the wild-type insulin receptor or different PKC iso-
forms ((31, [32, e, and Q was cloned into a cytomegalovirus promoter 
based expression vector and plasmid DNA was prepared using a 
Qiagen Plasmid Kit. Human embryonic kidney (HEK) 293 cells 
(ATCC CRL 1573) were grown in Dulbecco's MEM/nutrient mix 
F12 medium supplemented with 10% fetal calf serum. A total of 
4 ug plasmid DNA was transfected per semiconfluent 35 mm diameter 
dish according to the protocol of Chen and Okayama [16]. Cultures 
were maintained overnight at 37°C, 3% CO2. Rat-1 fibroblasts were 
grown in 35 mm diameter dishes in DMEM-F12 medium supple-
mented with 10% fetal calf serum and 2 mM glutamine 20 h before 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 1 3 5 7 - 4 
120 M. Kellerer et al.lFEBS Letters 418 (1997) 119-122 
Fig. 1. TNFa induced translocation of PKC e. Immunoblot show-
ing the protein level of cPKC e (upper panel) and the insulin recep-
tor p subunit (lower panel) in the plasma membrane fraction of rat-
1 flbroblasts overexpressing the human insulin receptor. Cells were 
incubated with 10 -9 M TNFa for the times indicated. Plasma mem-
brane fractions were separated by 7.5% SDS-PAGE and transferred 
to nitrocellulose. Nitrocelluloses were probed against a PKC e spe-
cific or insulin receptor specific antibody as described. A representa-
tive immunoblot of three independent experiments is shown. 
the experiment, the medium was changed to Dulbecco's MEM/nu-
trient mix F12 medium without FCS. 
2.2. Stimulation of cells and separation of proteins 
HEK293 cells and rat-1 flbroblasts were incubated with 10~9 M 
TNFa and 10~7 M insulin as indicated. Subsequently, cells were lysed 
in 200 nl lysis buffer (50 uM HEPES pH 7.2, 150 mM NaCl, 1 mM 
EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 100 mM NaF, 10 
mM sodium pyrophosphate, 100 uM sodium orthovanadate, 1 mM 
PMSF, 10 ng/ml aprotinin). 
For membrane preparation the same lysis buffer was used but with-
out Triton X-100. The cells were centrifuged at 14000Xg for 30 min 
and the pellet was solubilized with lysis buffer containing 1% Triton 
X-100. All lysates were centrifuged for 10 min at 14000Xg, 40 ul of 
the supernatant was taken, 5XLaemmli buffer added, boiled for 
5 min, and separated by 7.5% SDS-PAGE. 
2.3. Western blotting 
After electrophoresis, proteins were transferred to nitrocellulose by 
electroblotting (transfer buffer: 20 mM NaH 2P0 4 and 20 mM 
Na2HP04, pH 8.8). After transfer, the nitrocelluloses were blocked 
with NET buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 0.05% 
Triton X-100 and 0.25% gelatin, pH 7.4) for 1 h. Subsequently, they 
were incubated with the first antibodies (aPY20, aCT104 or PKC 
antibodies in NET buffer) overnight at 4°C. The nitrocellulose mem-
branes were washed 4x10 min with NET buffer before incubating 
with horseradish peroxidase conjugated anti-rabbit IgG (for polyclo-
nal antibody) or anti-mouse IgG (for monoclonal antibody) for 1 h at 
room temperature. Visualization of immune complexes was performed 
by ECL. To remove antibodies before reblotting the nitrocellulose was 
incubated in 62.5 mM Tris-HCl, pH 6.8, 2% SDS and 100 mM 0-
mercaptoethanol for 30 min at 55°C. 
3. Results 
TNFa induced PKC translocation was described earlier 
[13]. In this report the PKC isoform which responds to 
TNFa was not identified. In order to test the effect of 
TNFa on the subcellular distribution of PKC isoforms we 
prepared plasma membrane preparations from rat-1 flbro-
blasts overexpressing the human insulin receptor. To stand-
ardize the plasma membrane protein content we used the hu-
man insulin receptor as a marker protein. Fig. 1 shows that 
TNFa induced a rapid increase of the PKC isoform e in the 
plasma membrane fraction suggesting a translocation of this 
PKC isoform. The lower panel showing the immunoblot of 
HIR demonstrates that equal amounts of plasma membrane 
protein are applied. TNFa had no effect on translocation of 
other PKC isoforms in rat-1 flbroblasts (data not shown). 
In order to determine the impact of TNFa induced PKC e 
translocation on the activity of the insulin receptor we co-
transfected HEK293 cells with insulin receptor, IRS-1 and 
PKC E. Control cells were transfected with HIR and IRS-1 
alone or together with PKC (31, (32 or £. Fig. 2A shows insulin 
stimulated HIR and IRS-1 phosphorylation in these cells both 
in the absence and presence of 10~9 M TNFa. All cells have 
been stimulated with insulin (10~7 M) and an inhibitory effect 
Fig. 2. Inhibition of insulin receptor autophosphorylation by TNFa. HEK293 cells were transfected with cDNA for the human insulin recep-
tor, IRS-1 and different PKC isoforms as indicated. Transfected HEK293 cells were stimulated with insulin (10~7 M, 5 min) alone (—) or after 
preincubation (+) with 10~9 M TNFa for 10 min. Whole cell lysates were separated on a 7.5% SDS-PAGE, blotted onto nitrocellulose and 
probed against anti-phosphotyrosine antibody (A). Lysates from transfected cells were also probed with pan-PKC (crossreacts with (31, |}2 and 
C, PKC, but not e PKC) and PKC e antibody (B) indicating the expression levels of PKC isoenzymes. 
















Fig. 3. Quantification of the insulin receptor kinase inhibition. Den-
sitometric data are shown as mean ± S.E.M. of five independent ex-
periments. Tyrosine phosphorylation of the insulin receptor in the 
presence of insulin (10-7 M, 5 min) was taken as 100% in all cells 
transfected with the different PKC isoforms. The effect of TNFa is 
expressed as percent inhibition of this value. Statistical analysis was 
performed by Student's Mest for paired samples. 
of TNFa is seen in cells transfected with HIR and IRS-1 (Fig. 
2A, Co). Earlier results were also confirmed by cotransfection 
of the insulin receptor with the PKC isoforms pi or P2 which 
cause a decrease of the insulin stimulated receptor autophos-
phorylation [7]. In contrast, cotransfection of HIR and IRS-1 
with PKC e or PKC C, showed no significant reduction of 
insulin induced receptor autophosphorylation compared to 
control cells which were transfected only with HIR and 
IRS-1 (Fig. 2A). A slight tendency to increased insulin recep-
tor autophosphorylation was observed by cotransfection with 
PKC C (Fig. 2A). Different inhibition of HIR- and IRS-1 
phosphorylation is seen after short term incubation with 
TNFa in cells cotransfected with PKC isoforms (Fig. 2A). 
While TNFa had only a small inhibitory effect on cells trans-
fected with PKC pi , (32 and £, a clear inhibition was found in 
control cells, which was even more pronounced in cells trans-
fected with PKC e (Fig. 2A). Lysates were also blotted against 
anti-pan-PKC and anti-PKC e antibodies which confirm over-
expression of the corresponding PKC isoforms (Fig. 2B). 
Quantification of the data (n - 5) showed that only cotrans-
fection with PKC e can augment the inhibitory effect of 
TNFa (Fig. 3). These data suggest that PKC e is able to 
interact in an inhibitory way with the insulin receptor/IRS-1 
signaling chain after TNFa induced translocation. 
4. Discussion 
Studies in different cell systems have shown that TNFa 
inhibits insulin signaling at least partially by serine phospho-
rylation of IRS-1 [17-19]. It is at present unknown which 
serine kinase is involved in this effect. A role of PKC £, which 
is activated by TNFa stimulated ceramides, was discussed 
[14,15]. Beside this, ceramides are also able to activate protein 
phosphatases [20] which are also involved in the inhibitory 
effect of TNFa on insulin signaling as we have shown earlier 
[21]. However, a specific protein phosphatase has not been 
identified yet. We have observed a rapid inhibition of insulin 
receptor autophosphorylation and IRS-1 phosphorylation in 
rat-1 fibroblasts, NIH3T3 cells and HEK293 cells transfected 
with HIR and incubated with TNFa [21]. Since the unspecific 
PKC inhibitor H7 was not able to antagonize the inhibitory 
effect of TNFa we concluded that inhibition of insulin signal-
ing by TNFa is unlikely to occur via activation of PKC. On 
the other hand there are reports demonstrating that TNFa is 
able to induce translocation of protein kinase C [13] and cer-
amide, a product of the TNFa stimulated sphingomyelinase 
has also been shown to activate PKC £ [14,15]. These obser-
vations prompted us to readdress the question whether PKC 
dependent mechanisms might contribute to the crosstalk be-
tween the TNFa and insulin receptors. 
The presented data suggest that in addition to the above 
described mechanisms a PKC e dependent effect might indeed 
be important. This confirms the earlier observations of 
Kronke et al. [13] showing translocation of PKC by TNFa 
and demonstrates now an involvement of PKC e for at least 
part of the inhibitory effect of TNFa. It is possible that 
TNFa induced PKC e translocation enables this isoform to 
interact with the insulin receptor or IRS-1 probably in addi-
tion to other mechanisms. The insulin receptor kinase inhib-
ition by TNFa is not enhanced by other PKC isoforms. In 
particular, we could not demonstrate reduced phosphoryla-
tion of the insulin receptor and IRS-1 after transfection 
with PKC t, which can be activated by ceramides [14,15]. In 
contrast, cotransfection of PKC £ with HIR and IRS-1 shows 
a slight increase of tyrosine phosphorylation in HEK293 cells. 
Furthermore, after cotransfection of PKC isoform pi a less 
pronounced inhibition by TNFa compared to control cells 
was observed. This can be due to the fact that human insulin 
receptor activity is already suppressed by cotransfection with 
this PKC isoform. TNFa and PKC p might use same signal-
ing ways for HIR inhibition which are already maximally 
activated by overexpression of PKC pi. In contrast PKC e 
further enhances the inhibition of the insulin receptor auto-
phosphorylation after TNFa stimulation in HEK293 cells. 
The mechanism of this increased TNFa effect is still unclear. 
A direct phosphorylation of IRS-1 on serine residues by PKC 
e or activation of protein phosphatases seems possible and 
requires further studies. 
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